Key facts
- This page summarizes Jason Coloma V's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Sep 2026, 16:24.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Sale
Sale
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
The reported transaction represents shares of the Issuer's Common Stock sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $27.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.055 to $27.40 per share, inclusive.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.743 to $26.65 per share, inclusive.
Footnote F5
These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.
Footnote F6
These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.